Science & Technology
Developing Brain Penetrable AAV Gene Therapy for Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41NS145933-01
Award Ceiling
$500K
Award Floor
$500K
Close Date
Aug 31, 2026
169 days leftTotal Funding
$500K
Expected Awards
1
Posted Date
Sep 1, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R41NS145933-01
Description
STTR Phase Phase I award: "Developing Brain Penetrable AAV Gene Therapy for Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)" awarded to Galibra Neuroscience, Inc. in CHESTNUT HILL, Massachusetts. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $500,000. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.